This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.
A series of 3-aryl-4-indolylmaleimide IDH1/R132H inhibitors with a novel structure was obtained by high-throughput screening and structure-based optimization. Most compounds such as 7a, 7d, 7h, 7i, 7k and 7o showed high inhibitory effects on IDH1/R132H and were highly selective against IDH1/WT, IDH2/WT, GDH, GK, and FBP. Evaluation of the biological activities and function at cellular level showed
Synthesis and DNA binding profile of N-mono- and N,N′-disubstituted indolo[3,2-b]carbazoles
作者:Harmanpreet Kaur Panesar、Jennifer Solano、Thomas G. Minehan
DOI:10.1039/c4ob02566k
日期:——
N-Monosubstituted andN,N′-disubstituted indolo[3,2-b]carbazole derivatives bind DNA with micromolar to submicromolar affinities and a preference for intercalation at purine-pyrimidine steps.
Synthesis and Biological Evaluation of the 1-Arylpyrazole Class of σ<sub>1</sub> Receptor Antagonists: Identification of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1<i>H</i>-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)
作者:José Luis Díaz、Rosa Cuberes、Joana Berrocal、Montserrat Contijoch、Ute Christmann、Ariadna Fernández、Adriana Port、Jörg Holenz、Helmut Buschmann、Christian Laggner、Maria Teresa Serafini、Javier Burgueño、Daniel Zamanillo、Manuel Merlos、José Miguel Vela、Carmen Almansa
DOI:10.1021/jm3007323
日期:2012.10.11
yl}morpholine (S1RA, E-52862), which showed high activity in the mouse capsaicin model of neurogenicpain, emerged as the most interesting candidate. In addition, compound 28 exerted dose-dependent antinociceptive effects in several neuropathic pain models. This, together with its good physicochemical, safety, and ADME properties, led compound 28 to be selected as clinical candidate.
ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
申请人:Leivers Martin Robert
公开号:US20090226398A1
公开(公告)日:2009-09-10
Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.